Table 2.
Analysis of the influencing factors of pregnancy, neonatal complications and child death
| Characteristic | Pregnancy/fetal | 95%CI | P | New born complication | 95%CI | P | Child deaths | 95%CI | P | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | No | OR | Yes | No | OR | Yes | No | OR | ||||||||
| Age (years) | > 30 | 10 | 3 | 0.95 | 0.125–7.275 | 1 | 10 | 3 | 7.78 | 1.2–50.424 | 0.04 | 3 | 7 | 3 | 0.248–36.325 | 0.588 |
| ≤ 30 | 7 | 2 | 3 | 7 | 1 | 7 | ||||||||||
| Tumor stage | IV | 10 | 2 | 3.33 | 0.319–34.830 | 0.538 | 7 | 5 | 2.1 | 0.251–17.594 | 0.62 | 2 | 9 | NA | NA | 1 |
| I–III | 3 | 2 | 2 | 3 | 0 | 4 | ||||||||||
| Exposed gestational stage | 1st trim | 0 | 2 | NA | NA | 0.043 | 0 | 2 | NA | NA | 0.178 | 0 | 2 | NA | NA | 1 |
| others | 17 | 3 | 13 | 8 | 2 | 14 | ||||||||||
| Trastuzumab schedule | 3 weeks | 15 | 4 | 1.88 | 0.134–26.320 | 1 | 11 | 9 | 0.61 | 0.047–7.882 | 1 | 4 | 12 | NA | NA | 1 |
| 1 week | 2 | 1 | 2 | 1 | 0 | 2 | ||||||||||
| Exposed time (weeks) | ≤ 12 | 5 | 2 | 0.63 | 0.079–4.959 | 1 | 2 | 5 | 0.18 | 0.026–1.279 | 0.169 | 0 | 4 | NA | NA | 0.524 |
| > 12 | 12 | 3 | 11 | 5 | 4 | 10 | ||||||||||
| Total dose (mg) | ≤ 3000 | 2 | 3 | NA | NA | 0.061 | 1 | 4 | 0.13 | 0.008–1.998 | 0.242 | 0 | 2 | NA | NA | 1 |
| > 3000 | 6 | 0 | 4 | 2 | 1 | 5 | ||||||||||
| Chemotherapy | Yes | 5 | 1 | 1.67 | 0.147–18.874 | 1 | 3 | 3 | 0.7 | 0.108–4.538 | 1 | 0 | 4 | NA | NA | 0.524 |
| No | 12 | 4 | 10 | 7 | 4 | 10 | ||||||||||
| Endocrine therapy | Yes | 2 | 0 | NA | NA | 1 | 3 | 0 | NA | NA | 0.526 | 2 | 1 | 13 | 0.771–219.107 | 0.108 |
| No | 15 | 5 | 12 | 8 | 2 | 13 | ||||||||||
1st trim. the first trimester, NA not applicable